Target density, not affinity or avidity of antigen recognition, determines adoptive t cell therapy outcomes in a mouse lymphoma model

Journal of Immunology

Volumn 196, Issue 9, 2016, Pages 3935-3942

  Segal, Gabriela ^a   Prato, Sandro ^a   Zehn, Dietmar ^b,c   Mintern, Justine D ^d   Villadangos, Jose A ^a,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Swiss Vaccine Research Institute   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR; ANTIGEN; CANCER VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; DRUG TARGETING; LYMPHOMA; LYMPHOMA CELL; MALE; MOUSE; MOUSE MODEL; NONHODGKIN LYMPHOMA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOTOXICITY; DENDRITIC CELL; DISEASE MODEL; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PROCEDURES; TRANSPLANTATION;

ANIMALS; ANTIGENS; CANCER VACCINES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOMA; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84974803146     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1502187     Document Type: Article

References (34)

1. Maus, M. V., J. A. Fraietta, B. L. Levine, M. Kalos, Y. Zhao, and C. H. June. 2014. Adoptive immunotherapy for cancer or viruses. Annu. Rev. Immunol. 32: 189-225.
2. Restifo, N. P., M. E. Dudley, and S. A. Rosenberg. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12: 269-281.
3. Bos, R., K. L. Marquardt, J. Cheung, and L. A. Sherman. 2012. Functional differences between low-and high-affinity CD8(+) T cells in the tumor environment. OncoImmunology 1: 1239-1247.
4. Dutoit, V., V. Rubio-Godoy, P. Y. Dietrich, A. L. Quiqueres, V. Schnuriger, D. Rimoldi, D. Liénard, D. Speiser, P. Guillaume, P. Batard, et al. 2001. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res. 61: 5850-5856.
5. Zehn, D., S. Y. Lee, and M. J. Bevan. 2009. Complete but curtailed T-cell response to very low-affinity antigen. Nature 458: 211-214.
6. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93: 4102-4107.
7. Kessels, H. W., M. C. Wolkers, M. D. van den Boom, M. A. van der Valk, and T. N. Schumacher. 2001. Immunotherapy through TCR gene transfer. Nat. Immunol. 2: 957-961.
8. Amos, S. M., C. P. Duong, J. A. Westwood, D. S. Ritchie, R. P. Junghans, P. K. Darcy, and M. H. Kershaw. 2011. Autoimmunity associated with immunotherapy of cancer. Blood 118: 499-509.
9. Morgan, R. A., N. Chinnasamy, D. Abate-Daga, A. Gros, P. F. Robbins, Z. Zheng, M. E. Dudley, S. A. Feldman, J. C. Yang, R. M. Sherry, et al. 2013. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36: 133-151.
10. Linette, G. P., E. A. Stadtmauer, M. V. Maus, A. P. Rapoport, B. L. Levine, L. Emery, L. Litzky, A. Bagg, B. M. Carreno, P. J. Cimino, et al. 2013. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122: 863-871.
11. Prato, S., J. D. Mintern, M. H. Lahoud, D. C. Huang, and J. A. Villadangos. 2011. Induction of antigen-specific effector-phase tolerance following vaccination against a previously ignored B-cell lymphoma. Immunol. Cell Biol. 89: 595-603.
12. Prato, S., Y. Zhan, J. D. Mintern, and J. A. Villadangos. 2013. Rapid deletion and inactivation of CTLs upon recognition of a number of target cells over a critical threshold. J. Immunol. 191: 3534-3544.
13. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
14. Enouz, S., L. Carrié, D. Merkler, M. J. Bevan, and D. Zehn. 2012. Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection. J. Exp. Med. 209: 1769-1779.
15. Mueller, S. N., W. Heath, J. D. McLain, F. R. Carbone, and C. M. Jones. 2002. Characterization of two TCR transgenic mouse lines specific for herpes simplex virus. Immunol. Cell Biol. 80: 156-163.
16. Parish, I. A., J. Waithman, G. M. Davey, G. T. Belz, J. D. Mintern, C. Kurts, R. M. Sutherland, F. R. Carbone, and W. R. Heath. 2009. Tissue destruction caused by cytotoxic T lymphocytes induces deletional tolerance. Proc. Natl. Acad. Sci. USA 106: 3901-3906.
17. Wilson, N. S., G. M. Behrens, R. J. Lundie, C. M. Smith, J.Waithman, L. Young, S. P. Forehan, A. Mount, R. J. Steptoe, K. D. Shortman, et al. 2006. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 7: 165-172.
18. Zehn, D., and M. J. Bevan. 2006. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 25: 261-270.
19. Speiser, D. E., D. T. Utzschneider, S. G. Oberle, C. Munz, P. Romero, and D. Zehn. 2014. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat. Rev. Immunol. 14: 768-774.
20. Brentville, V. A., R. L. Metheringham, B. Gunn, and L. G. Durrant. 2012. High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment. PLoS One 7: e41112.
21. Kalergis, A. M., N. Boucheron, M. A. Doucey, E. Palmieri, E. C. Goyarts, Z. Vegh, I. F. Luescher, and S. G. Nathenson. 2001. Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat. Immunol. 2: 229-234.
22. Thomas, S., S. A. Xue, C. R. Bangham, B. K. Jakobsen, E. C. Morris, and H. J. Stauss. 2011. Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood 118: 319-329.
23. Lanzavecchia, A., G. Iezzi, and A. Viola. 1999. From TCR engagement to T cell activation: a kinetic view of T cell behavior. Cell 96: 1-4.
24. Valitutti, S., and A. Lanzavecchia. 1997. Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition. Immunol. Today 18: 299-304.
25. Valitutti, S., S. Muller, M. Cella, E. Padovan, and A. Lanzavecchia. 1995. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375: 148-151.
26. Dougan, S. K., M. Dougan, J. Kim, J. A. Turner, S. Ogata, H. I. Cho, R. Jaenisch, E. Celis, and H. L. Ploegh. 2013. Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity. Cancer Immunol. Res. 1: 99-111.
27. Zhong, S., K. Malecek, L. A. Johnson, Z. Yu, E. Vega-Saenz de Miera, F. Darvishian, K. McGary, K. Huang, J. Boyer, E. Corse, et al. 2013. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc. Natl. Acad. Sci. USA 110: 6973-6978.
28. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22: 329-360.
29. Schumacher, T. N., and R. D. Schreiber. 2015. Neoantigens in cancer immunotherapy. Science 348: 69-74.
30. Alexander-Miller, M. A., M. A. Derby, A. Sarin, P. A. Henkart, and J. A. Berzofsky. 1998. Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes. J. Exp. Med. 188: 1391-1399.
31. + CTL. Eur. J. Immunol. 31: 2951-2959.
32. Tay, S. S., Y. C. Wong, D. M. McDonald, N. A. Wood, B. Roediger, F. Sierro, C. Mcguffog, I. E. Alexander, G. A. Bishop, J. R. Gamble, et al. 2014. Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses. Proc. Natl. Acad. Sci. USA 111: E2540-E2549.
33. Roufaiel, M., J. W. Wells, and R. J. Steptoe. 2015. Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse? Front. Immunol. 6: 258.
34. + T cells without eliciting tissue-destructive effector function. J. Immunol. 184: 598-606.